about
An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulationNovel insights into the regulatory architecture of CD4+ T cells in rheumatoid arthritisA complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.Aggressive adult T cell leukemia/lymphoma: the tip of the iceberg of the hidden human T cell lymphotropic virus type 1 infection burden in nonendemic countries.Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study.Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.Circulating Cell-Derived Microparticles in Women with Pregnancy Loss[Is the endothelial circulating microparticles analysis enough to assess the inflammatory status related to preeclampsia?][Endothelial dysfunction and circulating microparticles in patients with antiphospholipid antibodies]Circulating cell-derived microparticles in severe preeclampsia and in fetal growth restriction[Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission]
P50
Q33511764-F873D727-979B-47F0-9AC5-2F3149DE5BDAQ33886177-341087BD-3965-4148-A631-E5B1B71E5688Q35061209-F1EC5A76-8C98-4C42-AF52-64DD623D3049Q35193842-90940D36-125D-4B3D-9417-0CBEE26278F7Q36799192-B9BED6B6-8C74-4C5A-A1C2-87CF3E0A1050Q42363684-67A02537-D3FD-47FE-A3A6-CB3F7E199E1AQ45353546-8426F49C-9947-439C-836F-C900FD8F7262Q50875043-D491F36A-E2BC-4112-B2F8-E36025B759ABQ51608422-F2535B6A-5432-40EE-9C78-F9A04546A1CCQ51749083-5F8EAB3C-4420-486D-87E3-AEE7AD4472E7Q61971104-90A146CE-681C-492F-B117-0E73740760E8Q83082410-138C6B37-8A4F-4292-AF33-B77CCB8D34A8Q84974356-14F8A634-C799-48B9-89FA-42DDD00A21D9Q85082389-B3BB93E1-7B72-4974-A572-F74FBD83D3FEQ94462959-B7928B7F-3F8C-41F8-B1DE-472A21EB2B18
P50
description
researcher (ORCID 0000-0002-9085-3327)
@en
wetenschapper
@nl
name
Carlos Palacio
@en
Carlos Palacio
@nl
type
label
Carlos Palacio
@en
Carlos Palacio
@nl
prefLabel
Carlos Palacio
@en
Carlos Palacio
@nl
P31
P496
0000-0002-9085-3327